← SynDRA
IBUTAMOREN
SynDRA canonical compound SYN0000665 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | GH1 | GHR | GHSR |
|---|
| Mechanism of action | growth hormone secretagogue receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- GHSR AGONIST
- Ghrelin receptor agonist
- growth hormone secretagogue receptor agonist
- GHSR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADGRF1
- NTHL1
- HTR1A
- HTR1D
- HTR1E
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- HTR6
- MC4R
- NEIL1
- NEIL2
- OPRD1
- ADRA1A
- OPRK1
- OPRM1
- S1PR1
- SIGMAR1
- SLC6A2
- SLC6A3
- SLC6A4
- SMUG1
- TDG
- TMEM97
- TSPO
- HRH4
- HRH3
- HRH2
- HRH1
- ADRA1B
- ADRA1D
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- ADRB3
- AGTR1
- APLNR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Ibutamoreno
- L-163,191
- L-163191
- MK-0667
- MK-677
- 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
- ibutamoren (nflis-drug)
- GJ0EGN38UL
- L 163,191
- ibutamoreno
- ibutamorenum
- RefChem:55388
- DTXCID0089191
- Ibutamoren [INN]
- MK-677, (HCl salt)
- UNII-GJ0EGN38UL
- MK677
- MK-677;Crescendo;MK 0677;MK-0677;MK0677
- IBUTAMOREN [WHO-DD]
- SCHEMBL739398
- GTPL5867
- IBUTAMOREN (MK-677)
- IBUTAMOREN [NFLIS-DRUG]
- SCHEMBL29369919
- BDBM50049478
- BDBM50403624
- HY-10199A
- AKOS025401779
- NCGC00263115-01
- NCGC00263115-05
- NCGC00263115-08
- NCGC00263115-10
- AC-25509
- CS-0002502
- NS00125727
- BRD-K44771174-066-01-0
- 1KD
- LUM-201
Look up IBUTAMOREN in the interactive SynDRA portal →